Jennison Associates LLC Has $119.41 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Jennison Associates LLC raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 42.5% during the third quarter, HoldingsChannel.com reports. The firm owned 4,198,554 shares of the company’s stock after buying an additional 1,252,451 shares during the quarter. Jennison Associates LLC’s holdings in NewAmsterdam Pharma were worth $119,407,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Mather Group LLC. bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth $30,000. Wolverine Asset Management LLC bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at $69,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of NewAmsterdam Pharma by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after purchasing an additional 662 shares during the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in NewAmsterdam Pharma by 51.7% in the second quarter. KLP Kapitalforvaltning AS now owns 9,100 shares of the company’s stock worth $165,000 after purchasing an additional 3,100 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $33.32 on Friday. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00. The company has a fifty day moving average price of $35.71 and a 200 day moving average price of $30.95. The stock has a market cap of $3.78 billion, a P/E ratio of -16.25 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 75,117 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57. Following the completion of the transaction, the chief accounting officer owned 15,000 shares of the company’s stock, valued at $543,150. This represents a 83.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the sale, the insider owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This represents a 7.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 153,647 shares of company stock worth $5,484,253 over the last 90 days. Corporate insiders own 20.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Citigroup boosted their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday. Stifel Nicolaus increased their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, The Goldman Sachs Group upped their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.